Literature DB >> 31061568

Levels of α-2 Macroglobulin in cognitively normal Mexican- Americans with Subjective Cognitive Decline: A HABLE Study.

James R Hall1,2, April R Wiechmann3, Leigh A Johnson1,2, Melissa L Edwards4, Sid E O'Bryant1,2.   

Abstract

BACKGROUND: The presence of Subjective Cognitive Decline (SCD) in the absence of objective change and the inflammatory biomarker Alpha 2 Macroglobulin (A2M) have both been implicated in preclinical Alzheimer's disease. Mexican Americans are population with high rates of cardiovascular and inflammatory disorders.
OBJECTIVES: The current study investigated the levels of A2M in cognitively normal Mexican Americans with and without complaints of cognitive decline.
METHOD: 293 (243 females, 50 males) community-based cognitively normal older Mexican Americans from the ongoing Health and Aging Brain among Latino Elders (HABLE) study were grouped based on subjective cognitive decline and blood samples were assayed by electrochemiluminescence to determine levels of A2M.
RESULTS: Participants with SCD had significantly higher levels of A2M than those without SCD. Females with SCD had a significantly higher level of A2M.
CONCLUSIONS: Results suggest that higher levels of A2M, a marker of neuronal injury, may be involved in subtle changes in cognitive functioning recognizable to persons reporting SCD but too subtle to be objectively measured. Longitudinal research is needed to assess the impact of SDC and A2M in progression to MCI and dementia in Mexican Americans.

Entities:  

Keywords:  Alpha 2 Macroglobulin; Mexican Americans; Subjective Cognitive Decline

Year:  2019        PMID: 31061568      PMCID: PMC6499402     

Source DB:  PubMed          Journal:  Curr Neurobiol        ISSN: 0975-9042


  25 in total

Review 1.  alpha2-macroglobulin in late-onset Alzheimer's disease.

Authors:  D M Kovacs
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

Review 2.  Biomarkers for preclinical Alzheimer's disease.

Authors:  Chen-Chen Tan; Jin-Tai Yu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression.

Authors:  Hongqian Yang; Yaroslav Lyutvinskiy; Sanna-Kaisa Herukka; Hilkka Soininen; Dorothea Rutishauser; Roman A Zubarev
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Influence of Alpha-2-Macroglobulin 5 bp I/D and Ile1000Val polymorphisms on the susceptibility of Alzheimer's disease: a systematic review and meta-analysis of 52 studies.

Authors:  Hui Chen; Zhongxuan Li; Nan Liu; Weiwei Zhang; Guangming Zhu
Journal:  Cell Biochem Biophys       Date:  2014-09       Impact factor: 2.194

5.  A blood-based algorithm for the detection of Alzheimer's disease.

Authors:  Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; James Hall; C Munro Cullum; Rachelle Doody; Thomas Fairchild; Perrie Adams; Kirk Wilhelmsen; Ramon Diaz-Arrastia
Journal:  Dement Geriatr Cogn Disord       Date:  2011-08-24       Impact factor: 2.959

6.  Functional analysis of plasma alpha(2)-macroglobulin from Alzheimer's disease patients with the A2M intronic deletion.

Authors:  Caroline Hope; Joseph Mettenburg; Steven L Gonias; Steven T DeKosky; M Ilyas Kamboh; Charleen T Chu
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

7.  AD dementia risk in late MCI, in early MCI, and in subjective memory impairment.

Authors:  Frank Jessen; Steffen Wolfsgruber; Birgitt Wiese; Horst Bickel; Edelgard Mösch; Hanna Kaduszkiewicz; Michael Pentzek; Steffi G Riedel-Heller; Tobias Luck; Angela Fuchs; Siegfried Weyerer; Jochen Werle; Hendrik van den Bussche; Martin Scherer; Wolfgang Maier; Michael Wagner
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

Review 8.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study.

Authors:  Steven J Kiddle; Martina Sattlecker; Petroula Proitsi; Andrew Simmons; Eric Westman; Chantal Bazenet; Sally K Nelson; Stephen Williams; Angela Hodges; Caroline Johnston; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Stephen Newhouse; Simon Lovestone; Richard J B Dobson
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI.

Authors:  Sid E O'Bryant; Guanghua Xiao; Robert Barber; Ryan Huebinger; Kirk Wilhelmsen; Melissa Edwards; Neill Graff-Radford; Rachelle Doody; Ramon Diaz-Arrastia
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

Review 10.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

Authors:  Sid E O'Bryant; Veer Gupta; Kim Henriksen; Melissa Edwards; Andreas Jeromin; Simone Lista; Chantal Bazenet; Holly Soares; Simon Lovestone; Harald Hampel; Thomas Montine; Kaj Blennow; Tatiana Foroud; Maria Carrillo; Neill Graff-Radford; Christoph Laske; Monique Breteler; Leslie Shaw; John Q Trojanowski; Nicole Schupf; Robert A Rissman; Anne M Fagan; Pankaj Oberoi; Robert Umek; Michael W Weiner; Paula Grammas; Holly Posner; Ralph Martins
Journal:  Alzheimers Dement       Date:  2014-10-01       Impact factor: 21.566

View more
  1 in total

1.  Proteomic Profiling of Plasma and Brain Tissue from Alzheimer's Disease Patients Reveals Candidate Network of Plasma Biomarkers.

Authors:  Mei Chen; Weiming Xia
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.160

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.